What's behind the "great abandonment" in gene therapy R&D? How does a startup spend $213 million? And is Adam an optimist?
We talk about all that and more on this week's episode of "The Readout LOUD." STAT biotech reporter Jonathan Wosen joins us to discuss gene therapy pioneer Jim Wilson's exit from his decades-long tenure at the University of Pennsylvania. We also discuss the latest news in the life sciences, including the surprising collapse of a gene editing company, Eli Lilly's pitch to consumers, and more.
Listen Now
For more on Wosen's interview with Jim Wilson, go here; for more on Tome Biosciences' financial struggles, go here; for details about its layoffs, go here; to learn more about how Eli Lilly's push from weight loss injections to vials could ease supply constraints, go here; and for analysis on the Zepbound pricing changes, go here.
Subscribe to the podcast to never miss an episode
Visit the archive to see past episodes
No comments